Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan

Hozumi Kumagai, Hitoshi Kusaba, Yuta Okumura, Masato Komoda, Michitaka Nakano, Shingo Tamura, Mayako Uchida, Kenichiro Nagata, Shuji Arita, hiroshi ariyama, Shigeo Takaishi, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.

元の言語英語
ページ(範囲)461-465
ページ数5
ジャーナルAsian Pacific Journal of Cancer Prevention
15
発行部数1
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

fosaprepitant
aprepitant
Dexamethasone
Japan
Safety
Drug Therapy
Serotonin 5-HT3 Receptor Antagonists
Antiemetics
Vomiting
Therapeutics

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

これを引用

Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan. / Kumagai, Hozumi; Kusaba, Hitoshi; Okumura, Yuta; Komoda, Masato; Nakano, Michitaka; Tamura, Shingo; Uchida, Mayako; Nagata, Kenichiro; Arita, Shuji; ariyama, hiroshi; Takaishi, Shigeo; Akashi, Koichi; Baba, Eishi.

:: Asian Pacific Journal of Cancer Prevention, 巻 15, 番号 1, 01.01.2014, p. 461-465.

研究成果: ジャーナルへの寄稿記事

Kumagai, Hozumi ; Kusaba, Hitoshi ; Okumura, Yuta ; Komoda, Masato ; Nakano, Michitaka ; Tamura, Shingo ; Uchida, Mayako ; Nagata, Kenichiro ; Arita, Shuji ; ariyama, hiroshi ; Takaishi, Shigeo ; Akashi, Koichi ; Baba, Eishi. / Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan. :: Asian Pacific Journal of Cancer Prevention. 2014 ; 巻 15, 番号 1. pp. 461-465.
@article{40337261502f4845842683288c638b9e,
title = "Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan",
abstract = "Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100{\%} and 85.4{\%} in the acute phase, and were 75.0{\%} and 64.6{\%} in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.",
author = "Hozumi Kumagai and Hitoshi Kusaba and Yuta Okumura and Masato Komoda and Michitaka Nakano and Shingo Tamura and Mayako Uchida and Kenichiro Nagata and Shuji Arita and hiroshi ariyama and Shigeo Takaishi and Koichi Akashi and Eishi Baba",
year = "2014",
month = "1",
day = "1",
doi = "10.7314/APJCP.2014.15.1.461",
language = "English",
volume = "15",
pages = "461--465",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan

AU - Kumagai, Hozumi

AU - Kusaba, Hitoshi

AU - Okumura, Yuta

AU - Komoda, Masato

AU - Nakano, Michitaka

AU - Tamura, Shingo

AU - Uchida, Mayako

AU - Nagata, Kenichiro

AU - Arita, Shuji

AU - ariyama, hiroshi

AU - Takaishi, Shigeo

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.

AB - Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.

UR - http://www.scopus.com/inward/record.url?scp=84894032707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894032707&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2014.15.1.461

DO - 10.7314/APJCP.2014.15.1.461

M3 - Article

C2 - 24528075

AN - SCOPUS:84894032707

VL - 15

SP - 461

EP - 465

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 1

ER -